Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effects of Inulin-Based Prebiotics on Gut Microbiota After Rectal Cancer Surgery (PUMCH-1-YSY)

14. November 2026 aktualisiert von: Guole Lin, Peking Union Medical College Hospital

Effects of Inulin-Based Compound Prebiotics on Postoperative Gut Microbiota Dysbiosis in Patients With Rectal Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Postoperative gut microbiota dysbiosis is a common clinical concern in patients undergoing rectal cancer surgery and may contribute to gastrointestinal dysfunction and postoperative complications. Inulin-based compound prebiotics may help maintain intestinal microbial balance by promoting beneficial bacteria and modulating gut microbial composition. However, their efficacy and safety in preventing postoperative gut microbiota dysbiosis in patients with rectal cancer remain to be established.

This study is a multicenter, randomized, double-blind, placebo-controlled, three-arm clinical trial designed to evaluate the efficacy and safety of inulin-based compound prebiotics in preventing gut microbiota dysbiosis following radical rectal cancer surgery and to assess their effects on gut microbiota composition.

A total of 261 adult patients with histologically confirmed rectal adenocarcinoma undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma will be enrolled at three study centers. Eligible participants will be randomly assigned in a 1:1:1 ratio to one of three groups: (1) inulin-based compound prebiotics combined with probiotics, (2) probiotics combined with placebo, or (3) placebo alone. Study interventions will be administered from postoperative day 1 through day 5.

The primary outcome is the incidence of gut microbiota dysbiosis within five days after surgery. Secondary outcomes include changes in gut microbiota composition and diversity, inflammatory markers, and fecal short-chain fatty acid levels. Gut microbiota will be assessed using 16S rRNA gene sequencing and metagenomic sequencing. Safety will be evaluated through the monitoring and recording of adverse events throughout the intervention period.

This study aims to provide clinical evidence regarding the efficacy and safety of inulin-based compound prebiotics for preventing postoperative gut microbiota dysbiosis and their potential role in modulating intestinal microbial homeostasis in patients undergoing rectal cancer surgery.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

261

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Beijing, China, 100730
        • Peking Union Medical College Hospital
        • Kontakt:
      • Beijing, China, 100000
        • Beijing Friendship Hospital, Capital Medical University
        • Kontakt:
      • Beijing, China, 100007
        • Beijing Sixth Hospital
        • Kontakt:
          • Yi An
          • Telefonnummer: 010-13621224452

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Adults aged 18 years or older.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 before surgery.
  3. Histologically confirmed rectal adenocarcinoma diagnosed by endoscopic biopsy, with the lower margin of the tumor located ≤12 cm from the anal verge.
  4. Undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma.
  5. Willing and able to provide written informed consent, understand and comply with study requirements and procedures, and not currently participating in another clinical study considered by the investigator to conflict with this study.

Exclusion Criteria:

  1. Known intolerance to inulin or prebiotics.
  2. History of severe irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
  3. Presence of distant metastases, including liver or lung metastases.
  4. Severe intestinal obstruction, gastrointestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency treatment.
  5. Undergoing open radical rectal cancer surgery or conversion from laparoscopic to open surgery.
  6. Use of antibiotics (excluding planned perioperative antibiotic prophylaxis), prebiotics, probiotics, synbiotic products, or immunosuppressive agents within one month before surgery.
  7. Severe cardiovascular, cerebrovascular, hepatic, renal, pulmonary, or hematopoietic system diseases.
  8. Pregnant or breastfeeding women.
  9. Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Inulin-Based Compound Prebiotics Plus Probiotics

Participants in this group will receive oral inulin-based compound prebiotics (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), combined with compound Lactobacillus enteric-coated capsules (0.66 g three times daily) and a triple viable Bifidobacterium preparation (0.42 g three times daily). All interventions will be administered from postoperative day 1 through day 5.

An oral inulin-based compound prebiotic supplement containing inulin (62.5%), polydextrose (10%), allulose (10%), isomaltooligosaccharides (7.88%), tagatose (7.75%), hyaluronic acid (1.25%), and chitosan oligosaccharides (0.63%). Participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g orally twice daily on postoperative days 2-5. The intervention will be administered in combination with probiotic preparations in the experimental group.

An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

Aktiver Komparator: Probiotics Plus Placebo

Participants in this group will receive compound Lactobacillus enteric-coated capsules (0.66 g orally three times daily) and a triple viable Bifidobacterium preparation (0.42 g orally three times daily), combined with maltodextrin placebo administered at the same dosage and schedule as the inulin-based compound prebiotics group. All interventions will be administered from postoperative day 1 through day 5.

An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens.

Placebo-Komparator: Placebo

Participants in this group will receive oral maltodextrin placebo (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), together with additional maltodextrin placebo (0.66 g and 0.42 g, each administered orally three times daily) to match the probiotic preparations used in the other groups. All interventions will be administered from postoperative day 1 through day 5.

Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Postoperative Gut Microbiota Dysbiosis
Zeitfenster: Postoperative days 1-5

The primary outcome is the proportion of participants who develop gut microbiota dysbiosis within five days following laparoscopic radical rectal cancer surgery with a protective intestinal stoma. Postoperative gut microbiota dysbiosis will be assessed based on clinical manifestations, including abdominal distension, diarrhea or increased stoma output, abdominal pain, fever, nausea, and vomiting, together with relevant laboratory findings. The incidence will be calculated as the number of participants diagnosed with postoperative gut microbiota dysbiosis divided by the total number of participants evaluated in each treatment group, expressed as a percentage.

Postoperative days 1-5

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes in Gut Microbiota Composition and Diversity
Zeitfenster: Preoperatively and on postoperative days 3 and 5

Changes in gut microbiota composition and diversity will be assessed using metagenomic sequencing of fecal samples collected before surgery and during the postoperative period. Gut microbiota composition will be evaluated based on changes in microbial community structure and the relative abundance of bacterial taxa, while microbial diversity will be assessed using diversity indices derived from sequencing data. Changes in gut microbiota composition and diversity will be compared among the three treatment groups.

Preoperatively and on postoperative days 3 and 5
Changes in the Bifidobacterium-to-Escherichia coli Ratio (B/E Ratio)
Zeitfenster: Preoperatively and on postoperative days 3 and 5

The Bifidobacterium-to-Escherichia coli ratio (B/E ratio) in fecal samples will be assessed using gut microbiota sequencing data. Changes in the B/E ratio will be compared among the three treatment groups to evaluate alterations in intestinal microbial balance following surgery.

Preoperatively and on postoperative days 3 and 5
Serum C-Reactive Protein (CRP) Level
Zeitfenster: Preoperatively and on postoperative days 3 and 5

Serum C-reactive protein (CRP) levels will be measured to assess postoperative inflammatory responses. CRP concentrations will be compared among the three treatment groups. Results will be reported in mg/L.

Preoperatively and on postoperative days 3 and 5
Serum Procalcitonin (PCT) Level
Zeitfenster: Preoperatively and on postoperative days 3 and 5

Serum procalcitonin (PCT) levels will be measured as an indicator of postoperative inflammatory responses. PCT concentrations will be compared among the three treatment groups. Results will be reported in ng/mL.

Preoperatively and on postoperative days 3 and 5
Serum Interleukin-6 (IL-6) Level
Zeitfenster: Preoperatively and on postoperative days 3 and 5

Serum interleukin-6 (IL-6) levels will be measured to evaluate postoperative inflammatory responses. IL-6 concentrations will be compared among the three treatment groups. Results will be reported in pg/mL.

Preoperatively and on postoperative days 3 and 5
Fecal Short-Chain Fatty Acid (SCFA) Levels
Zeitfenster: Preoperatively and on postoperative days 3 and 5

Fecal concentrations of short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, will be measured to assess gut microbial metabolic activity. Changes in individual SCFA concentrations before and after surgery will be compared among the three treatment groups.

Preoperatively and on postoperative days 3 and 5

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

20. November 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2027

Studienabschluss (Geschätzt)

30. Juni 2028

Studienanmeldedaten

Zuerst eingereicht

14. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. November 2026

Zuerst gepostet (Tatsächlich)

20. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be shared with other researchers due to participant privacy and confidentiality considerations and the absence of an approved data-sharing plan.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren